These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39196656)

  • 1. Real-world experience of abemaciclib for adjuvant and metastatic breast cancer.
    Drowne T; Armgardt E; Svoboda A
    J Oncol Pharm Pract; 2024 Aug; ():10781552241279189. PubMed ID: 39196656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
    Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
    Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
    Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.
    Fung S; Blair HA
    Target Oncol; 2023 Mar; 18(2):287-294. PubMed ID: 36826463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer.
    Sammons S; Moore H; Cushman J; Hamilton E
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):805-814. PubMed ID: 35737886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
    Rugo HS; Huober J; García-Sáenz JA; Masuda N; Sohn JH; Andre VAM; Barriga S; Cox J; Goetz M
    Oncologist; 2021 Jan; 26(1):e53-e65. PubMed ID: 32955138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib.
    Jacobs F; Agostinetto E; Solferino A; Torrisi R; Masci G; Santoro A; De Sanctis R
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.
    Davie A; Traoré S; Giovannitti M; Pompilio G; Lambton M; Cakar E; Chatterjee A
    Glob Reg Health Technol Assess; 2023; 10():62-69. PubMed ID: 37811343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
    J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
    Paluch-Shimon S; Neven P; Huober J; Cicin I; Goetz MP; Shimizu C; Huang CS; Lueck HJ; Beith J; Tokunaga E; Contreras JR; de Sant'Ana RO; Wei R; Shahir A; Nabinger SC; Forrester T; Johnston SRD; Harbeck N
    Ther Adv Med Oncol; 2023; 15():17588359231151840. PubMed ID: 36756142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
    Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T; Becerra C; Kalinsky K; Moore KN; Manuel AM; Lithio A; Price GL; Chapman SC; Litchfield LM; Goetz MP
    Front Oncol; 2021; 11():810023. PubMed ID: 35223458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.
    Raheem F; Ofori H; Simpson L; Shah V
    Ann Pharmacother; 2022 Feb; ():10600280211073322. PubMed ID: 35135362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study.
    Magnoni F; Corso G; Maisonneuve P; Bianchi B; Accardo G; Sangalli C; Massari G; Rotili A; Nicosia L; Pesapane F; Montagna E; Mazzarol G; Galimberti V; Veronesi P; Curigliano G
    EClinicalMedicine; 2024 May; 71():102552. PubMed ID: 38545425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
    Ring A; Karuturi M; Smyth EN; Lokhandwala T; Sheffield KM; Willey J; Lunacsek O; Sapunar F; Cui ZL; Coutinho AD; Rybowski S
    Drugs Real World Outcomes; 2023 Dec; 10(4):589-603. PubMed ID: 37775689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of Adjuvant Treatment with Abemaciclib-Real-World Data from a Large German Breast Center.
    Dannehl D; Volmer LL; Weiss M; Matovina S; Grischke EM; Oberlechner E; Seller A; Walter CB; Hahn M; Engler T; Brucker SY; Hartkopf AD
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
    Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey Emilio J
    Farm Hosp; 2024; 48(2):75-78. PubMed ID: 37735004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abemaciclib as adjuvant treatment for high-risk early breast cancer.
    Ganfornina Andrades A; Fénix Caballero S; Salguero Olid A; Alegre Del-Rey EJ
    Farm Hosp; 2024; 48(2):T75-T78. PubMed ID: 38114413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR
    Yuan Y; Zhang S; Wang T; Wang B; Wang S; Shi J; Sun T; Yin Y; Ouyang Q; Li J; Wen Y; Zhang L; Jiang Z
    Transl Breast Cancer Res; 2023; 4():10. PubMed ID: 38751483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
    Tolaney SM; Guarneri V; Seo JH; Cruz J; Abreu MH; Takahashi M; Barrios C; McIntyre K; Wei R; Munoz M; Antonio BS; Liepa AM; Martin M; Johnston SRD; Kellokumpu-Lehtinen PL; Harbeck N
    Eur J Cancer; 2024 Mar; 199():113555. PubMed ID: 38244363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.